Barclays Maintains Overweight on Celldex Therapeutics, Lowers Price Target to $50
Benzinga Newsdesk 16 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Barclays analyst Etzer Darout maintains Celldex Therapeutics (NASDAQ:CLDX) with a Overweight and lowers the price target from $53 to $50.
More on CLDX
FDA & biotech Benzinga
Celldex Drops Atopic Dermatitis Study Following Weak Phase 2 Pruritus DataCelldex halts barzolvolimab development in atopic dermatitis after Phase 2 trial misses primary itch reduction goals despite strong safety.

Benzinga
Celldex Reports Topline Results From Phase 2 Study Of Barzolvolimab In Atopic Dermatitis; Study Did Not Meet Key Efficacy Measures Or Internal Hurdle Rate For Continued DevelopmentStudy did not meet key efficacy measures or internal hurdle rate for continued developmentSystemic mast cell depletion observed, consistent with prior studies, as evidenced by significant reduction…
Analyst ratings Benzinga
HC Wainwright & Co. Maintains Buy on Celldex Therapeutics, Lowers Price Target to $58HC Wainwright & Co. analyst Joseph Pantginis maintains Celldex Therapeutics (NASDAQ:CLDX) with a Buy and lowers the price target from $64 to $58.
